Dean & Company is a strategy consulting firm with a unique mix of both traditional business strategy work and a range of investing activities for large corporations, technology start-ups, and equity funds. We work with senior executives to dramatically improve and sustain their company's performance. Dean & Company has an established, highly successful track record in generating actionable and quantifiable results for our clients in the Life Sciences. These include a number of the largest global companies as well as emerging leaders in the Pharmaceuticals, Biotechnology, and Medical Devices & Technology industries. We additionally have developed specialized expertise in the Vaccines industry. The hallmark of our work in life sciences, as in other industries, is our ability to deliver highly quantitative, analytic-driven solutions to complex business problems and the development of practical, action-oriented recommendations and their associated measurable impact on the bottom-line. Our life sciences capabilities extend across the following industry challenges and issues: Licensing/Strategic Alliances/M&A Due Diligence, Portfolio/Life Cycle Management, Product Commercialization & Launch, Manufacturing & Distribution Strategy, Competitive Intelligence/Benchmarking, Marketing Strategy, Pricing & Reimbursement, R&D Productivity.

EvaluatePharma® is the premier source for commercial analysis in the pharma and biotech sector, delivering exclusive, trusted insight into industry performance. For industry insiders and the investment sector, EvaluatePharma® supports value-enhancing business decisions with unrivalled proprietary insight.

EvaluatePharma® sets new industry standards by providing consensus forecasts on global drug sales. Our expertise and innovative approach has driven other pioneering developments including Merge Company tool, Calendar of Events and interactive NPV Analyzer.

But it's not just our expertise that sets us apart. The reliability of our data and depth of coverage provide clients with commercial insights simply not available anywhere else.

IntraLinks® provides enterprise-class solutions which facilitate the secure, compliant and auditable exchange of critical information, collaboration and workflow management inside and outside the enterprise. Our on-demand solutions help you organize, manage, share and track information, enabling you to accelerate your workflow, optimize your business processes and realize new profit potential. Since 1997, IntraLinks has been used on critical business processes by more than 750,000 users from 90,000 organizations worldwide, including 10 of the top 10 pharmaceutical companies and hundreds of biotechs. IntraLinks counts 800 of the Fortune 1000 as clients, including enterprises such as AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more information, visit www.intralinks.com.

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 15,000 professionals located at 16 sites throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients.

At sanofi-aventis, each and every day we work for what really matters: health.

Upsher-Smith is continually looking for strong and trusted partnerships through licensing, joint ventures, profit sharing, co-development and comarketing arrangements. Upsher-Smith has a unique & effective U.S. commercialization strategy through a wide, multi-channel distribution network, experienced sales force and established customer base within all customer segments.

Looking to the future, Upsher-Smith is focused on:

• Building the current pipeline of ANDA's, 505(b)2, and other low-cost alternative products
• Adding women’s health products ready for immediate or near-term commercialization and promotion to OB/GYNs
• Developing, in-licensing and acquiring CNS products focused primarily on treatments for epilepsy & Parkinson’s disease.

Upsher-Smith is committed to the development and growth of innovative products. Our focus is simple: Advancing pharmacotherapy. Improving life.™

Over 25 years, ZS Associates has helped clients in more than 70 countries measurably improve their results, through our comprehensive expertise in sales and marketing consulting, capability building, and outsourcing. Our clients include multinational, midsize and entrepreneurial companies around the world, with a deep and long-standing emphasis on the healthcare sector, and the pharma/biotech sector in particular. Through our business development and licensing practice area, we support both large and small pharma/biotech companies with services ranging from strategic portfolio evaluation and business development strategy to evaluation of specific potential partners and deals. ZS has more than 1,000 professionals serving clients from 17 offices worldwide. (www.zsassociates.com)